Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy.

Abstract

BACKGROUND/AIM:

Cabazitaxel is recommended as first-line treatment after docetaxel for metastatic castration-resistant prostate cancer. However, the efficacy, adverse events and prognostic factors associated with cabazitaxel are unclear.

PATIENTS AND METHODS:

This single-centre retrospective study including 30 patients with CRPC treated with cabazitaxel between 2014 and 2020 investigated efficacy, outcomes and prognostic factors.

RESULTS:

Fourteen patients had visceral metastases. The median cabazitaxel dose was 20 mg/m2 The prostate-specific antigen response rate, time to prostate-specific antigen response, and overall survival were 13.3%, 3.48 months, and 7.92 months, respectively. The rates of grade 3 or more neutropenia and febrile neutropenia were 20% and 6.7%, respectively. By multivariate analysis, sarcopenia and visceral metastasis at the time of cabazitaxel initiation were independent and significant factors conferring a poor prognosis.

CONCLUSION:

The early introduction of cabazitaxel, prior to the development of sarcopenia and visceral metastasis, might contribute to improved prognosis in CRPC.

• Authors: Hiroaki Iwamoto, Hiroshi Kano, Takafumi Shimada, Renato Naito, Tomoyuki Makino, Suguru Kadomoto, Hiroshi Yaegashi, Kazuyoshi Shigehara, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami
• Journal: In vivo (Athens, Greece) (In Vivo) 2021 May-Jun Vol. 35 Issue 3 Pg. 1703-1709 ISSN: 1791-7549 [Electronic] Greece
• PMID: 33910855 (Publication Type: Journal Article)
• Copyright: Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Taxoids
• cabazitaxel

Topics

• Humans
• Male
• Neoplasm Metastasis
• Prognosis
• Prostatic Neoplasms, Castration-Resistant (drug therapy)
• Retrospective Studies
• Sarcopenia
• Taxoids
• Treatment Outcome